Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Melanoma treatment details. Immunotherapy. Virginia Commonwealth University, Richmond Virgina, United States



Survival: 10.0 months
   
Toxicity Grade: 3
   
Treatments: Immunotherapy
   
Drugs: Proleukin
Country: United States
   
City/State/Province: Richmond Virgina
   
Hospital: Virginia Commonwealth University
   
Journal: Link
   
Date: 1/2006

Description:
Patients: This phase 2 study involved 26 patients with advanced cutaneous melanoma (all with the Human Leukocyte Antigen genotype).

Treatment: Treatment consisted of immunotherapy - melanoma peptide vaccination (g209-2M) and low dose interleukin-2.

Toxicity: Toxicities included: grade 3 hypertension, arrhythmia, rash and nausea.

Results: Overall median survival was 10 months and no responses were reported. This study demonstrated that the combination of g209-2M and low-dose IL-2 is not active in melanoma. A preliminary report released subsequent to initiation of this study suggested that the combination of g209-2M and high-dose IL-2 is less effective than previously suggested.

Correspondence: Dr. John D. Roberts

E-mail to a Friend Email Physician More Information